Other GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio PharmaphorumA court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Rejuvenate crowdfunds development of gene therapy for aging, chronic diseasesNext: Jazz Pharmaceuticals receives FDA Priority Review for Ziihera combo in first-line HER2+ GEA Related Stories Other ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer pharminent June 2, 2026 Other ASCO26: Symptom-tracking app helps advanced cancer patients pharminent June 2, 2026 Other All eyes on Revolution, bispecific antibodies and more at ASCO26 pharminent May 26, 2026
